5 High Growth Pharmaceutical Stocks Holding Analysts' Confidence

|
 |  Includes: AEGR, HZNP, KERX, PCRX, RIGL
by: ZetaKap

Interested in pharmaceutical stocks? Do you prefer stocks that analysts rate as 'Buy', or better? Do you prefer stocks that can bring in profits over the next year? For ideas on how to start your own search, we ran a screen.

EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. The 1-Year Expected EPS Growth Rate is an annual growth estimate, where the growth projections are made by analysts, the company or other credible sources.

We first looked for pharmaceutical stocks. From here, we then looked for companies that analysts rate as "Buy" or "Strong Buy" (mean recommendation < 3). Next, we then screened for businesses that have high future earnings per share growth forecasts(1-year projected EPS Growth Rate>25%). We did not screen out any market caps.

Do you think these stocks will offer healthy returns? Use our list along with your own analysis.

1) Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $446.02M
Beta: -
Click to enlarge

Pacira Pharmaceuticals Inc. has a Analysts' Rating of 1.40, and a 1-Year Projected Earnings Per Share Growth Rate of 80.60%. The short interest was 8.08% as of 06/12/2012. Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, commercialization, and manufacture of pharmaceutical products for use in hospitals and ambulatory surgery centers. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its product portfolio includes EXPAREL, a long-acting non-opioid postsurgical analgesic for postsurgical pain management; DepoCyt for the treatment of lymphomatous meningitis, a cancer of the immune system; DepoDur for controlling post operative pain; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis oncology.

2) Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $351.08M
Beta: -
Click to enlarge

Aegerion Pharmaceuticals, Inc. has a Analysts' Rating of 1.70, and a 1-Year Projected Earnings Per Share Growth Rate of 45.40%. The short interest was 4.12% as of 06/12/2012. Aegerion Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood.

3) Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $560.88M
Beta: 1.48
Click to enlarge

Rigel Pharmaceuticals, Inc. has a Analysts' Rating of 1.60, and a 1-Year Projected Earnings Per Share Growth Rate of 27.10%. The short interest was 6.59% as of 06/12/2012. Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (NYSE:SYK) inhibitor that is in Phase III clinical trials for rheumatoid arthritis; R343, an inhaled SYK inhibitor, which completed Phase I clinical trials for asthma; R333, a topical JAK/SYK inhibitor, which is in Phase I clinical trials for the treatment of discoid lupus; and R548, an oral janus kinase 3 (JAK3) inhibitor that in Phase I clinical trials for the treatment of transplant rejection and other immune disorders. The company's research/preclinical programs comprise R348, a soluble JAK/SYK inhibitor for topical ophthalmic use; R256, an inhaled interleukin 13 signaling inhibitor for chronic asthma; an oral activator of adenosine monophosphate activated protein kinase for enhancing the body's energy utilization and restore muscle endurance in chronically ill subjects; and growth/differentiation factor 8 inhibitor to prevent muscle loss.

4) Horizon Pharma, Inc. (NASDAQ:HZNP)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $141.88M
Beta: -
Click to enlarge

Horizon Pharma, Inc. has a Analysts' Rating of 1.30, and a 1-Year Projected Earnings Per Share Growth Rate of 52.70%. The short interest was 10.83% as of 06/12/2012. Horizon Pharma, Inc., a biopharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers DUEXIS for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and LODOTRA/RAYOS for the treatment of moderate to severe active rheumatoid arthritis in adults when accompanied by morning stiffness. It also develops LODOTRA/RAYOS, which is under Phase 2 clinical trial for the treatment of polymyalgia rheumatica.

5) Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $122.45M
Beta: 3.24
Click to enlarge

Keryx Biopharmaceuticals Inc. has a Analysts' Rating of 1.40, and a 1-Year Projected Earnings Per Share Growth Rate of 30.30%. The short interest was 14.37% as of 06/12/2012. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company's products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types.

*Company profiles were sourced from Finviz. Financial data was sourced from Finviz and Yahoo Finance.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.